CSIMarket
 


Fibrogen Inc   (FGEN)
Other Ticker:  
 

Fibrogen Inc 's Working Capital Ratio

FGEN's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 1.74 below Fibrogen Inc average.

Within Major Pharmaceutical Preparations industry 427 other companies have achieved higher Working Capital Ratio than Fibrogen Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 1134 to 2666.

Explain Working Capital Ratio
How much in Current Assets FGEN´s has?
What is the value of FGEN´s Current Liabilities?


FGEN Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -16.9 % -19.25 % -0.25 % 21.32 % 20.39 %
Y / Y Current Assets Change -23.22 % -20.99 % -17.9 % 3.96 % -17.3 %
Working Capital Ratio MRQ 1.74 2.12 1.69 1.8 1.88
FGEN's Total Ranking # 2666 # 1134 # 2604 # 2600 # 2574
Seq. Current Liabilities Change 7.91 % -23.82 % -6.88 % 8.56 % 4.85 %
Seq. Current Assets Change -11.49 % -4.46 % -12.64 % 3.92 % -8.92 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 428
Healthcare Sector # 833
Overall Market # 2666


Working Capital Ratio Statistics
High Average Low
11.14 5.12 1.69
(Mar 31 2020)   (Mar 31 2023)




Financial Statements
Fibrogen Inc 's Current Liabilities $ 209 Millions Visit FGEN's Balance sheet
Fibrogen Inc 's Current Assets $ 364 Millions Visit FGEN's Balance sheet
Source of FGEN's Sales Visit FGEN's Sales by Geography


Cumulative Fibrogen Inc 's Working Capital Ratio

FGEN's Working Capital Ratio for the trailling 12 Months

FGEN Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -16.9 % -19.25 % -0.25 % 21.32 % 20.39 %
Y / Y Current Assets TTM Growth -23.22 % -20.99 % -17.9 % 3.96 % -17.3 %
Working Capital Ratio TTM 1.82 1.86 1.88 1.97 2.05
Total Ranking TTM # 3998 # 1899 # 2284 # 1104 # 1929
Seq. Current Liabilities TTM Growth 7.91 % -23.82 % -6.88 % 8.56 % 4.85 %
Seq. Current Assets TTM Growth -11.49 % -4.46 % -12.64 % 3.92 % -8.92 %


On the trailing twelve months basis In spite of the year on year decrease in FGEN's Current Liabilities to $209.42 millions, cumulative Working Capital Ratio to 1.82 below the FGEN average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 502 other companies have achieved higher Working Capital Ratio than Fibrogen Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 1899 to 3998.

Explain Working Capital Ratio
How much in Current Assets FGEN´s has?
What is the value of FGEN´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 503
Healthcare Sector # 1046
Within the Market # 3998


trailing twelve months Working Capital Ratio Statistics
High Average Low
9.16 5.5 1.82
(Jun 30 2018)   (Sep 30 2023)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Pacira Biosciences inc   4.78 $ 447.255  Millions$ 93.661  Millions
Siga Technologies Inc  4.75 $ 145.971  Millions$ 30.745  Millions
Revance Therapeutics Inc   4.73 $ 388.519  Millions$ 82.158  Millions
Deciphera Pharmaceuticals Inc   4.67 $ 417.576  Millions$ 89.458  Millions
Spyre Therapeutics Inc   4.59 $ 205.949  Millions$ 44.872  Millions
Aclaris Therapeutics Inc   4.56 $ 123.068  Millions$ 27.010  Millions
Corvus Pharmaceuticals Inc   4.53 $ 33.094  Millions$ 7.299  Millions
Cartesian Therapeutics Inc   4.51 $ 89.869  Millions$ 19.939  Millions
Cara Therapeutics inc   4.49 $ 100.603  Millions$ 22.384  Millions
Arcturus Therapeutics Holdings Inc   4.49 $ 393.268  Millions$ 87.683  Millions
Imunon Inc   4.48 $ 21.725  Millions$ 4.846  Millions
Karyopharm Therapeutics Inc   4.47 $ 263.222  Millions$ 58.884  Millions
Axsome Therapeutics Inc   4.46 $ 511.763  Millions$ 114.662  Millions
Arcus Biosciences Inc   4.41 $ 882.000  Millions$ 200.000  Millions
Chemomab Therapeutics Ltd   4.39 $ 20.897  Millions$ 4.762  Millions
Nurix Therapeutics Inc   4.36 $ 267.949  Millions$ 61.493  Millions
Capricor Therapeutics inc   4.35 $ 29.527  Millions$ 6.792  Millions
Monopar Therapeutics Inc   4.32 $ 8.568  Millions$ 1.982  Millions
Syros Pharmaceuticals Inc   4.31 $ 122.515  Millions$ 28.394  Millions
Apellis Pharmaceuticals Inc   4.29 $ 796.767  Millions$ 185.630  Millions
Regulus Therapeutics Inc   4.25 $ 35.082  Millions$ 8.248  Millions
Intercept Pharmaceuticals inc   4.22 $ 383.445  Millions$ 90.845  Millions
Homology Medicines Inc  4.22 $ 106.635  Millions$ 25.292  Millions
Cyclerion Therapeutics Inc   4.21 $ 9.864  Millions$ 2.341  Millions
Protagenic Therapeutics Inc new  4.20 $ 5.377  Millions$ 1.280  Millions
Phio Pharmaceuticals Corp   4.13 $ 9.328  Millions$ 2.256  Millions
Synlogic Inc   4.13 $ 37.780  Millions$ 9.144  Millions
Harmony Biosciences Holdings inc   4.12 $ 462.998  Millions$ 112.408  Millions
Scisparc Ltd   4.10 $ 6.445  Millions$ 1.571  Millions
Blueprint Medicines Corporation  4.09 $ 808.172  Millions$ 197.384  Millions

Date modified: 2023-11-07T13:07:54+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com